Abstract：【Objective】 To investigate the clinical efficacy of Buyang Huanwu Decoction combined with edaravone dexborneol injection in the treatment of acute cerebral infarction (ACI).【Methods】A total of 90 ACI patients were randomly divided into the control group and the observation group, with 45 cases in each group. The control group received edaravone dexborneol injection, while the observation group received BYHWD in addition to the same treatment as the control group. Changes in carotid intima-media thickness (IMT), plaque area, Traditional Chinese Medicine (TCM) syndrome score, neurological deficit [National Institutes of Health Stroke Scale (NIHSS) score], quality of life [Modified Rankin Scale (MRS) score], and serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and neuron-specific enolase (NSE) were compared between the two groups before and after treatment.【Results】 After treatment, the observation group showed significantly lower carotid IMT, plaque area, TCM syndrome score, NIHSS score, mRS score, Lp-PLA2, and NSE levels compared to the control group (P<0.05).【Conclusion】Buyang Huanwu Decoction combined with edaravone dexborneol injection can effectively alleviate arterial lesions, improve TCM symptoms and neurological function, enhance quality of life, and reduce serum Lp-PLA2 and NSE levels in ACI patients, making it worthy of clinical promotion.
2025, Vol. 42 
